设计,合成针对瘤微环境中的β-葡萄糖酶的auristatins-glucuronide联合体
Yujie Wang1, Keshi Xu2, Hongchun Liu3
1School of Pharmacy, Fudan University, Shanghai 201203, China.
Bioorganic & medicinal chemistry letters
|October 4, 2023
概括
新的auristatin-glucuronide结合剂在瘤中准β-glucuronidase. 结合物20和21显示稳定性和强烈的抗癌活性,结合物20在没有副作用的小鼠模型中显示有效性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 向瘤微环境 (TME) 是癌症治疗的一个有希望的策略.
- 在各种固体瘤中,β-Glucuronidase (GUS) 过度表达,使其成为药物输送的有吸引力的标.
- 奥里斯塔丁是强大的细胞毒剂,但它们的全身管理受到毒性限制.
研究的目的:
- 为了合成和表征新型的奥里斯塔丁-葡萄胺结合物,用于GUS介导的TME中药物释放.
- 评估这些结合物的稳定性,药物释放动力学和体外抗增殖活性.
- 在临床前癌症模型中评估最有前途的结合物的体内抗瘤疗效和安全性.
主要方法:
- 合成奥里斯塔 - 葡萄胺联合体.
- 在酸盐缓冲体和牛血清中进行稳定性研究.
- 在体外抗增殖测定针对GUS预处理和未处理的癌细胞.
- 在HCT-116异种移植小鼠模型中进行的药理动力学分析和抗瘤疗效研究.
主要成果:
- 结合物20和21在生理条件下表现出极好的稳定性.
- 这些结合物具有很高的选择性,对GUS预处理的癌细胞具有强烈的活性 (IC50 = 5.79.7 nM),但对未经处理的细胞的活性很小 (IC50 > 1 μM).
- 结合剂20在HCT-116异种移植中显示出显著的瘤生长抑制,没有可观察到的不良影响.
结论:
- 可以有效地设计auristatin-glucuronide结合物,通过GUS激活向瘤微环境提供向药物.
- 结合物20和21代表有前途的候选药物,具有良好的疗效和安全性.
- 这些发现支持了GUS激活前药物改善癌症化疗的潜力.
相关概念视频
Phase II Reactions: Glucuronidation
484
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
484
Drug Metabolism: Phase II Reactions
3.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
264
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
264
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


